Get the Stockscreener App
100.34
2.37%
-2.44
Pre-market:
100.50
0.16
+0.16%
Jazz Pharmaceuticals Plc stock is traded at $100.34, with a volume of 610.72K.
It is down -2.37% in the last 24 hours and down -27.69% over the past month.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
See More
Previous Close:
$102.78
Open:
$102.11
24h Volume:
610.72K
Relative Volume:
0.59
Market Cap:
$6.18B
Revenue:
$3.99B
Net Income/Loss:
$463.16M
P/E Ratio:
14.13
EPS:
7.1
Net Cash Flow:
$1.10B
1W Performance:
-1.39%
1M Performance:
-27.69%
6M Performance:
-11.30%
1Y Performance:
-8.73%
1-Day Range:
$98.96
$102.48
1-Week Range:
$98.96
$104.53
52-Week Range:
$95.49
$148.06
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Name
Jazz Pharmaceuticals Plc
Sector
Industry
Phone
353-1-634-7800
Address
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Compare JAZZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
100.34 | 6.18B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Upgrade | UBS | Neutral → Buy |
| Feb-26-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-13-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-12-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Buy |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Nov-27-23 | Downgrade | UBS | Buy → Neutral |
| Sep-29-23 | Initiated | Raymond James | Mkt Perform |
| Jun-12-23 | Resumed | Wells Fargo | Equal Weight |
| Dec-09-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Buy |
| Apr-06-22 | Downgrade | Goldman | Buy → Neutral |
| Nov-19-21 | Resumed | Goldman | Buy |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Oct-05-21 | Initiated | Citigroup | Buy |
| Sep-23-21 | Initiated | Needham | Buy |
| May-19-21 | Resumed | JP Morgan | Overweight |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-03-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-29-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-09-20 | Reiterated | H.C. Wainwright | Buy |
| Sep-14-20 | Downgrade | Goldman | Neutral → Sell |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-06-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-28-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-06-20 | Initiated | Jefferies | Buy |
| Mar-12-20 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-08-20 | Initiated | Goldman | Neutral |
| Aug-21-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jun-11-19 | Initiated | Barclays | Overweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-18 | Reiterated | B. Riley FBR | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Jul-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-23-18 | Reiterated | H.C. Wainwright | Neutral |
| Mar-19-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Jazz Pharmaceuticals Plc Stock (JAZZ) Latest News
Jazz Pharmaceuticals Completes $935 Million Acquisition of Chimerix - marketscreener.com
Jazz Pharmaceuticals (JAZZ) Completes Acquisition of Chimerix - StreetInsider
Jazz Pharmaceuticals Completes Acquisition of Chimerix - TipRanks
Jazz Pharmaceuticals acquires Chimerix for $935 million - Investing.com
Jazz's $935M Chimerix Buyout Targets First-Ever Treatment for Rare Brain Cancer, FDA Verdict Looms - Stock Titan
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play? - Yahoo Finance
JAZZ Vs. HRMY: Which Neuroscience Drugmaker Is The Stronger Play? - Barchart.com
Jazz Sues Alvogen Seeking to Block Copy of Defitelio Liver Drug - Bloomberg Law News
JAZZ vs. ARGX: Which Stock Is the Better Value Option? - Yahoo Finance
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term - Yahoo Finance
Is Jazz Pharmaceuticals A Top Cannabis Investment For 2025? - Barchart.com
Is Jazz Pharmaceuticals a Top Cannabis Investment for 2025? - Zacks Investment Research
Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - GlobeNewswire Inc.
Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers - Yahoo Finance
Drug Resistant Epilepsy Market reached US$ 0.78 billion in 2022 - openPR.com
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Idiopathic Hypersomnia Treatment Market Set to Witness - openPR.com
Jazz Agrees To Fork Out $145m To Resolve Most Xyrem ‘Pay-For-Delay’ Claims - insights.citeline.com
BofA maintains Buy on Jazz Pharmaceuticals stock, target at $213 By Investing.com - Investing.com UK
Where Jazz Pharmaceuticals Stands With Analysts - Benzinga
Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last? - Nasdaq
Jazz Pharmaceuticals stock hits 52-week low at $99 By Investing.com - Investing.com Canada
Jazz Pharma inks $145M deal to resolve Xyrem antitrust claims - MSN
Jazz Pharmaceuticals at Needham Conference: Strategic Growth Insights By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals (JAZZ) Settles Antitrust Claims for $145M - GuruFocus
Jazz Pharma stock slips after $145M antitrust deal (JAZZ) - Seeking Alpha
JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time To Buy Or Sell? - Barchart.com
Jazz Pharmaceuticals stock hits 52-week low at $99 - Investing.com
JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell? - Yahoo Finance
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny - simplywall.st
Jazz Agrees To Pay $145M To Settle Xyrem Antitrust Fight - Law360
UBS cuts Jazz Pharmaceuticals stock price target to $166 By Investing.com - Investing.com UK
Potential Tariffs Pose Challenges for Jazz Pharmaceuticals (JAZZ) - GuruFocus
RBC Raises Price Target on Jazz Pharmaceuticals to $182 From $178, Keeps Outperform Rating - MarketScreener
Post-traumatic Stress Disorder Treatment Market Generated - openPR.com
After a year of 4.3% returns, Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) share price drop last week may have less of an impact on institutional investors - Yahoo Finance
JAZZ or ARGX: Which Is the Better Value Stock Right Now? - Yahoo Finance
Teacher Retirement System of Texas Buys 2,346 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Is Jazz Pharmaceuticals (JAZZ) the Best Mid Cap Biotech Stock to Buy? - Insider Monkey
Jazz (JAZZ) Down 9.2% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
10 Best Mid Cap Biotech Stocks to Buy - Insider Monkey
Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference - Eagle-Tribune
Dravet Syndrome Market Expected to Experience Major Growth - openPR
Is Jazz Pharmaceuticals plc (JAZZ) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
Focal Epilepsy Market: Analysis of Epidemiology, Pipeline - openPR
Axsome's ADHD drug meets main goal in late-stage study - Marketscreener.com
12 Most Promising Biotech Stocks According to Wall Street Analysts - Insider Monkey
Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term - Yahoo Home
Jazz strikes the chord with $935m Chimerix acquisition - BioXconomy
Jazz Pharmaceuticals Plc Stock (JAZZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):